General Information of the Compound
Compound ID
CP0205289
Compound Name
N-[5-[[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]sulfamoyl]-4-methyl-1,3-thiazol-2-yl]acetamide
    Show/Hide
Synonyms
SR-1001
TH17 cell inhibitor (multiple sclerosis), Scripps
    Show/Hide
Structure
Formula
C15H13F6N3O4S2
Molecular Weight
477.408
Canonical SMILES
CC(=O)Nc1nc(C)c(s1)S(=O)(=O)Nc1ccc(cc1)C(O)(C(F)(F)F)C(F)(F)F
    Show/Hide
InChI
InChI=1S/C15H13F6N3O4S2/c1-7-11(29-12(22-7)23-8(2)25)30(27,28)24-10-5-3-9(4-6-10)13(26,14(16,17)18)15(19,20)21/h3-6,24,26H,1-2H3,(H,22,23,25)
    Show/Hide
InChIKey
OZBSSKGBKHOLGA-UHFFFAOYSA-N
Physicochemical Property
logP
3.52292
Rotatable Bonds
5
Heavy Atom Count
30
Polar Areas
108.39
Hydrogen Bond Donor Count
3
Hydrogen Bond Acceptor Count
6
Complexity
30

"RO5" indicates the cutoff set by lipinski's rule of five:

(1) Molecular weight less than 500 Dalton;

(2) xlogp less than 5;

(3) No more than 5 hbonddonor (Hydrogen Bond Donor Count);

(4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count);

(5) No more than 10 rotbonds (Rotatable Bond Count).

    Show/Hide
Click to Show/Hide the External Link(s) of This Compound
PubChem ID
CID: 44241473
SID: 125319187
ChEMBL ID
CHEMBL3094388
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound

Compound
Cell Line
Protein

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT02658, Nuclear receptor ROR-alpha
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000006 HEK293 Homo sapiens (Human)  1
1
EC50 = 4000 nM
   TI
   LI
   LO
   TS
Biochemical Assays
1 Ki = 172 nM
Protein ID: PT02663, Nuclear receptor ROR-gamma
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000006 HEK293 Homo sapiens (Human)  1
1
EC50 = 4000 nM
   TI
   LI
   LO
   TS
Biochemical Assays
1 Ki = 111 nM
Clinical Information about the Compound
Drug 1 ( SR-1001 )
Drug Name SR-1001
Company Scripps Research Institute
Indication
Diabetic retinopathy
Preclinical
Multiple sclerosis
Investigative